Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association

被引：7

作者：

Kim, Hyun Jin ^{[1
]}

Park, Seok O. ^{[2
]}

Ko, Seung-Hyun ^{[3
]}

Rhee, Sang Youl ^{[4
]}

Hur, Kyu-Yeon ^{[5
]}

Kim, Nan-Hee ^{[6
]}

Moon, Min Kyong ^{[7
]}

Lee, Byung-Wan ^{[8
]}

Kim, Jin Hwa ^{[9
]}

Choi, Kyung Mook ^{[6
]}

机构：

[1] Chungnam Natl Univ, Div Endocrinol & Metab, Dept Internal Med, Sch Med, Daejeon, South Korea

[2] Gwangmyeong Sungae Hosp, Dept Internal Med, 36 Digital Ro, Gwangmyeong 14241, South Korea

[3] Catholic Univ Korea, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Seoul, South Korea

[4] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, Seoul, South Korea

[5] Sungkyunkwan Univ, Samsung Med Ctr,Sch Med, Div Endocrinol & Metab, Dept Internal Med, Seoul, South Korea

[6] Korea Univ, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Seoul, South Korea

[7] Seoul Natl Univ, Dept Internal Med, Seoul Metropolitan Govt Boramae Med Ctr, Coll Med, Seoul, South Korea

[8] Yonsei Univ, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Seoul, South Korea

[9] Chosun Univ, Div Endocrinol & Metab, Dept Internal Med, Coll Med, Gwangju, South Korea

来源：

DIABETES & METABOLISM JOURNAL | 2017年 / 41卷 / 06期

关键词：

Cardiovascular benefit; Clinical practice guideline; Combination therapy; Glucagon-like peptide-1 receptor agonist; Hypoglycemia; Monotherapy; RANDOMIZED CONTROLLED-TRIAL; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INSULIN GLARGINE; PHARMACOLOGICAL MANAGEMENT; DOUBLE-BLIND; EFFICACY; SAFETY; LIRAGLUTIDE; METFORMIN; DULAGLUTIDE;

D O I：

10.4093/dmj.2017.41.6.423

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

引用

页码：423 / 429

页数：7

共 50 条

[21] DIABETES AND OBESITY. THE ROLE OF AGONISTS GLUCAGON-LIKE PEPTIDE-1 OF IN THE TREATMENT OF TYPE 2 DIABETES
Petunina, Nina A.
Telnova, Milena E.
DIABETES MELLITUS, 2018, 21 (04): : 293 - 300
[22] Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review
Yammine, Luba
Kosten, Thomas R.
Pimenova, Maria
Schmitz, Joy M.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 149 : 78 - 88
[23] Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Xie, Zeyu
Hu, Jia
Li, Mengting
Hu, Xiao
Chen, Jisheng
RISK MANAGEMENT AND HEALTHCARE POLICY, 2024, 17 : 1053 - 1067
[24] THE EFFICACY OF TREATMENT WITH GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN CHRONIC DIALYSIS PATIENTS WITH DIABETES MELLITUS
Takeda, Kazuhito
Toyonaga, Jiro
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
[25] Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes
Niazi, Siar
Gnesin, Filip
Thein, Anna-Sophie
Andreasen, Jens R.
Horwitz, Anna
Mouhammad, Zaynab A.
Jawad, Baker N.
Niazi, Zia
Pourhadi, Nelsan
Zareini, Bochra
Meaidi, Amani
Torp-Pedersen, Christian
Kolko, Miriam
OPHTHALMOLOGY, 2024, 131 (09) : 1056 - 1063
[26] Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus
Tan, Xinrui
Pan, Xiongfeng
Wu, Xiaochuan
Zheng, Songjia
Chen, Yuyao
Liu, Donghai
Zhang, Xingxing
FRONTIERS IN PHARMACOLOGY, 2023, 14
[27] The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Win L. Yin
Steve C. Bain
Thinzar Min
Diabetes Therapy, 2020, 11 : 835 - 844
[28] Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Katherine A. Lyseng-Williamson
Clinical Drug Investigation, 2019, 39 : 805 - 819
[29] COPD Exacerbations in Patients With Type 2 Diabetes on Glucagon-like Peptide-1 Receptor Agonists
Foer, D.
Strasser, Z. H.
Cui, J.
Cahill, K. N.
Murphy, S. N.
Karlson, E. W.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[30] Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development
Ahren, Bo
JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (02) : 196 - 201

← 1 2 3 4 5 →